Bempedoic Acid
Corporate Commitment to Research and Development to Drive Innovation in Science
At ESPERION, our world-renowned team of experts are committed to Research and Development that will change the lipid management landscape. This has been the first major development program for ESPERION. You can read more about our pipeline below.

Development Timeline for Bempedoic Acid1-6
Bempedoic Acid
Oral, small molecule
elevated LDL-C
FDA Approval
Feb. 21, 2020
risk reduction

Cardiovascular Outcomes Trial ongoing
LDL-C=low-density lipoprotein cholesterol; CVD=cardiovascular disease.
On Feb. 21, 2020, the Food and Drug Administration (FDA) provided approval for the use of bempedoic acid.

5 Phase 3 trials ~4000 patients

References: 1. Data on file. Esperion Therapeutics, Inc. 2019. 2. Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR Outcomes). Accessed February 8, 2019. 3. Evaluation of long-term safety and tolerability of ETC-1002 in high-risk patients with hyperlipidemia and high CV risk (CLEAR Harmony). Accessed February 8, 2019. 4. Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) in patients with hyperlipidemia and statin intolerant (CLEAR Serenity). Accessed February 8, 2019. 5. Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) as add-on to ezetimibe therapy in patients with elevated LDL-C (CLEAR Tranquility). Accessed February 8, 2019. 6. Evaluation of long-term efficacy of bempedoic acid (ETC-1002) in patients with hyperlipidemia at high cardiovascular risk (CLEAR Wisdom). Accessed February 8, 2019.